Heather Rubino

Pfizer, Inc

Poster(s):

• (094) Concomitant prescribing of nirmatrelvir/ritonavir (NMV-r) and medications with potential risk for drug-drug interaction – a feasibility assessment of Truveta Electronic Health Records Database.
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (344) Interim results from the VAC4EU Post-Authorization Safety Study (PASS) among recipients of the Pfizer-BioNTech COVID-19 (Comirnaty®) vaccine in Europe
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (351) Preliminary Findings from a Feasibility and Capacity Assessment of Truveta® Studio using Flu Vaccine as Example: A Near Real-Time Electronic Health Records Database with Potential to Monitor Post-Approval Vaccine Safety
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST